| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
9-Phenanthrol targets the transient receptor potential melastatin 4 (TRPM4) channel, a Ca2+-activated non-selective cation channel. TRPM4 is involved in the regulation of membrane potential, calcium signaling, and various physiological processes including cardiac rhythm and vascular tone. The compound is selective for TRPM4 over TRPM5 at 100 μM. By inhibiting TRPM4, it modulates cellular excitability and calcium-dependent signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, 9-Phenanthrol inhibits TRPM4 channel activity. It is selective for TRPM4 over TRPM5 at 100 μM. The compound reduces heart rate in spontaneously beating isolated mouse right atria. It also reduces infarct size and apoptosis in isolated rat hearts in an ex vivo model of ischemia-reperfusion injury. These effects are attributed to TRPM4 inhibition in cardiac tissue.
|
| ln Vivo |
In vivo, 9-Phenanthrol reduces myogenic tone in rat cerebral arteries, suggesting a role in regulating vascular tone and blood flow. The compound has potential applications in studying cardiovascular function and TRPM4-mediated physiological processes. However, specific in vivo efficacy data are not extensively reported.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 9-Phenanthrol typically involve electrophysiological patch-clamp recordings of TRPM4 channel activity in HEK293 cells or other cell lines expressing TRPM4. Cells are voltage-clamped, and TRPM4 currents are elicited by voltage ramps or steps in the presence of intracellular Ca2+. The compound (typically 1-300 μM) is applied extracellularly, and current inhibition is measured. Selectivity over TRPM5 is assessed in parallel experiments.
|
| Cell Assay |
In vitro cellular assays for 9-Phenanthrol use cells expressing TRPM4 (e.g., HEK293 or CHO cells transfected with TRPM4). Cells are cultured in appropriate media and loaded with calcium indicators or used for patch-clamp recordings. Cells are treated with various concentrations of the compound (typically 1-100 μM), and TRPM4-mediated currents or calcium signals are measured. Cell viability is assessed using standard assays.
|
| Animal Protocol |
In vivo animal studies with 9-Phenanthrol use rodent models to assess cardiovascular effects. In isolated heart Langendorff perfusion models, hearts are perfused with buffer containing the compound (10-100 μM) to assess effects on heart rate and infarct size after ischemia-reperfusion. In vivo, cerebral artery myogenic tone is assessed using pressurized artery preparations from rats. The compound is administered intravenously or locally.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 9-Phenanthrol: The compound has a molecular weight of 194.23. Specific PK parameters are not extensively reported. As a small lipophilic molecule, it is expected to have good tissue penetration.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 9-Phenanthrol is not extensively reported. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include acute toxicity in rodents and assessment of cardiovascular effects.
|
| References | |
| Additional Infomation |
9-Phenylenol is a phenanthrene compound in which the hydrogen atom on the carbon atom of the central ring is replaced by a hydroxyl group. It is a TRPM4 channel inhibitor. 9-Phenylenol is derived from the hydride of phenanthrene. It has been reported that 9-Phenylenol has been found in Streptomyces flavovirens, and relevant data are available. This compound belongs to the phenanthrene and its derivatives family. These compounds are polycyclic compounds containing a phenanthrene ring, which is a tricyclic aromatic compound composed of three non-linearly fused benzene rings.
9-Phenanthrol (CAS 484-17-3) is a selective inhibitor of the TRPM4 channel with potential applications in cardiovascular research. It reduces heart rate, infarct size, and myogenic tone in ex vivo and in vivo models. The compound is available for research purposes only. |
| Molecular Formula |
C14H10O
|
|---|---|
| Molecular Weight |
194.2286
|
| Exact Mass |
194.073
|
| CAS # |
484-17-3
|
| PubChem CID |
10229
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
404.5±14.0 °C at 760 mmHg
|
| Melting Point |
139-143ºC
|
| Flash Point |
197.7±12.0 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.754
|
| LogP |
3.94
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DZKIUEHLEXLYKM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H10O/c15-14-9-10-5-1-2-6-11(10)12-7-3-4-8-13(12)14/h1-9,15H
|
| Chemical Name |
phenanthren-9-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~514.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1485 mL | 25.7427 mL | 51.4854 mL | |
| 5 mM | 1.0297 mL | 5.1485 mL | 10.2971 mL | |
| 10 mM | 0.5149 mL | 2.5743 mL | 5.1485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
